|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mechanism of allopurinol induced TPMT inhibition显示文摘 | P.A. Blaker M. Arenas-Hernandez M.A. Smith E.A. Shobowale-Bakre L. Fairbanks P.M. Irving J.D. Sanderson A.M. Marinaki | 2013 | Biochemical Pharmacology2013，，4： | 2 |
| 2 | Hepatitis C in hemodialysis patients显示文摘Despite reduction of hepatitis C prevalence after recognition of the virus and testing of blood products, hemodialysis(HD) patients still comprise a high risk group. The natural history of hepatitis C virus(HCV) infection in dialysis is not fully understood while the clinical outcome differs from that of the general population. HD patients show a milder liver disease with lower aminotransferase and viral levels depicted bymilder histological features on liver biopsy. Furthermore, the 'silent' clinical course is consistent with a slower disease progression and a lower frequency of cirrhosis and hepatocellular carcinoma. Potential explanations for the 'beneficial' impact of uremia and hemodialysis on chronic HCV infection are impaired immunosurveillance leading to a less aggressive host response to the virus and intradialytic release of 'hepatoprotective' cytokines such as interferon(IFN)-α and hepatocyte growth factor. However, chronic hepatitis C is associated with a higher liver disease related cardiovascular and allcause mortality of HD patients. Therapy is indicated in selected patients groups including younger patients with low comorbidity burden and especially renal transplant candidates, preferably after performance of a liver biopsy. According to current recommendations, choice of treatment is IFN or pegylated interferon with a reported sustained viral response at 30%-40% and a withdrawal rate ranging from 17% to 30%. New data regarding combination therapy with low doses of ribavirin which provide higher standard variable rates and good safety results, offer another therapeutic option. The new protease inhibitors may be the future for HCV infected HD patients, though data are still lacking. | Smaragdi Marinaki John N Boletis Stratigoula Sakellariou Ioanna K Delladetsima | 2015 | World Journal of Hepatology2015，7，3： | 2 |
| 3 | Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation:Experience of one center显示文摘AIM: To investigate the long-term results of ABOincompatible(ABOi) kidney transplantation in a single center in Greece.METHODS: Thirty consecutive ABOi kidney transplantations were performed from June 2005 to December 2013. All patients received rituximab one month prior to transplantation. Immunoadsorption therapy was performed for the removal of anti-A/B Ig G antibodies until the titer was ≤ 1:16. Additional apheresis sessions were performed post-operatively. Intravenous immunoglobulin and oral immunosuppression consisting of tacrolimus(TAC) in combination with either everolimus or mycophenolate acid was administered. We compared the long term results of our ABOi group to those of a matched group of 30 ABO compatible(ABOc) living kidney recipients with similar baseline characteristics. The ABOc recipients received an immunosuppressive regimen consisting of TAC and mycophenolate acid. All patients in both groups received induction therapy with Basiliximab or Daclizumab, whereas corticosteroids were instituted on the day of surgery. During the followup period, indication biopsies were performed and interpreted by an experienced nephropathologist. The parameters we analyzed included the following: Donor/recipient age, gender, blood type, human leukocyte antigen mismatches, panel reactive antibodies, primary cause of renal failure, mean time on dialysis, immunosuppressive regimen, patient survival, graft outcome, incidence of rejections, surgical and infectious complications.RESULTS: The mean follow-up period was 6 years(range 1 to 9 years). A mean of 5.0 ± 3.0(range 0-14) pre-transplant immunoadsorptions were required in order to reach the target titer. Patient survival in ABOi group in comparison to ABOc group at 1, 3, 5 and 8 years did not differ significantly(100% vs 100%, 96% vs 100%, 92% vs 100% and 92% vs 100%, P = ns). Additionally, graft survival was similar in the two groups at the same time points(100% vs 100%, 96% vs 96%, 92% vs 96% and 81% vs 92%, P = ns). The mean serum creatinine and the estimated glomerular filtration rate by the modification of diet in renal disease formula at 1, 3, 5 and 8 years did not differ significantly between ABOi and ABOc group. None of the patients in the ABOi group developed acute or chronic antibodymediated rejection evidenced by histological signs. Four patients(13.3%) in the ABOi group and 3(10%) in the ABOc group experienced acute cellular rejection, which was treated successfully in all cases. Bacterial and viral infections were also similar between the two groups.CONCLUSION: ABOi kidney transplantation is a safe and effective alternative that enables kidney transplantation in countries with unacceptably long deceaseddonor waiting lists. | Christina Melexopoulou Smaragdi Marinaki George Liapis Chrysanthi Skalioti Maria Gavalaki George Zavos John N Boletis | 2015 | World Journal of Transplantation2015，5，4： | 2 |
| 4 | A hybridization of clonal selection algorithm with iterated local search and variable neighborhood search for the feature selection problem 显示文摘 | MARINAKI M MARINAKIS Y | 2015 | Memetic Computing2015，7，3： | 1 |
| 5 | Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency显示文摘 | Marinaki AM Arenas M | 2002 | Hum Genet2002，111，45： | 1 |
| 6 | National survey of the current manage- ment of? infertility in women aged 40 and over in the UK 显示文摘 | Marinakis G Nikolaou D | 2012 | J Obstet GynaecoL2012，32，4： | 1 |
| 7 | A Hybrid Multi-Swarm Particle Swarm Optimization algorithm for the Probabilistic Traveling Salesman Problem显示文摘 | Yannis Marinakis Magdalene Marinaki | 2009 | Computers and Operations Research2009，，3： | 1 |
| 8 | Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPA)显示文摘 | Ansari A Duley JA | 2004 | Pharmacogenetics2004，14，3： | 1 |
| 9 | A hybrid multi-swarm particle swarm optimization algorithm for the probabilistie traveling salesman problem显示文摘 | Marinakis Y Marinaki M | 2010 | Computers and Operations Research2010，37，3： | 1 |
| 10 | Expanding neighborhood GRASP for the traveling salesman problem 显示文摘 | Marinakis Y Migdalas A Pardalos P M | 2005 | Computational Optimization and Applications2005，，32： | 1 |
| 11 | Honey bees mating optimization algorithm for financial classification problems 显示文摘 | Magdalene Marinaki Yannis Marinakis Constantin Zopounidis | 2010 | Applied Soft Computing2010，10，： | 1 |
| 12 | Model predictive control to alleviate thermal overloads显示文摘 | Otomega B Marinakis A Glavic M | 2007 | IEEE Transactions on Power Systems2007，22，3： | 1 |
| 13 | A building automation and control tool for remote and real time monitoring of energy consumption 显示文摘 | MARINAKIS V KARAKOSTA C DOUKAS H | 2013 | Sustainable Cities and Society2013，6，： | 1 |
| 14 | Phenotypes and enviromental factors: their influence in PCOS显示文摘 | Diamanti-Kandarakis E Christakou C Marinakis E | 2012 | Curr Pharm Des2012，18，3： | 1 |
| 15 | Particle swarm optimization with expanding neighborhood opology for the permutation flow- shop scheduling problem 显示文摘 | Marinakis Y Marinaki M | 2013 | Soft Computing2013，17，： | 1 |
| 16 | Phenotypes and Enviromental Factors: Their Influence in PCOS显示文摘 | Evanthia Diamanti-Kandarakis Charikleia Christakou Evangelos Marinakis | 2012 | Current Pharmaceutical Design2012，，3： | 1 |
| 17 | Particle swarm optimization for the vehicle routing problem with stochastic demands显示文摘 | Marinakis Y Iordanidou G R Marinaki M | 2013 | Applied Soft Computing2013，13，： | 1 |
| 18 | Pharmacogenetic associationwith adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation显示文摘 | Breen DP Marinaki AM Arenas M | 2005 | Liver Transpl2005，11，7： | 1 |
| 19 | A hybrid particle swarm optimization algorithm for the vehicle routing problem显示文摘 | MARINAKIS Y MARINAKI M DOUNIAS G | 2010 | En-gineering Applications of Altificial Intelligence2010，23，4： | 1 |
| 20 | Toutouzas Im- pact of abnormal nocturnal blood pressure fall on vascular function 显示文摘 | Marinakis AG Vyssoulis GP Michaelides AP | 2003 | A m J Hypertens2003，16，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员